Prolor Reports Positive Preclinical Results for Hemophilia Drug Candidate Print E-mail
By Staff and Wire Reports   
Tuesday, 14 February 2012 10:03
One of the companies whose shares have been rising as we have been watching it, PROLOR Biotech, Inc. (AMEX:PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
As you may recall, Prolor is applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. This particular study was designed to measure the potential increase in survival rates, thrombin levels and in vivo recovery of Factor VIIa-CTP when compared with commercially available recombinant Factor VIIa.

The "in vivo recovery" standard is a pharmacokinetic parameter used by researchers that compares actual clotting activity post-dosing to anticipated clotting activity. 

 

The new study showed that compared to commercially available Factor VIIa, hemophilic mice receiving PROLOR's Factor VIIa-CTP demonstrated:

  • A superior survival rate over a longer time period following a bleeding challenge.
  • Superior and longer-lasting generation of thrombin, a key pro-clotting enzyme.
  • Significantly higher in vivo recovery.

"The results of our second Factor VIIa-CTP preclinical study are consistent with the results we obtained from the previous study, and we believe they are very promising," noted Shai Novik, President of PROLOR. "With these positive results, we now have what we believe could be a highly competitive coagulation factor that could potentially become a leader in the hemophilia market."

As pointed out by the company's management, there is great need among hemophilia patients and their physicians for new therapies that will provide prolonged protection from bleeding. "The encouraging results seen in our preclinical hemophilia studies suggest that Factor VIIa-CTP may be able to offer an improved therapeutic option for hemophiliacs by reducing the frequency of injections, controlling bleeding more effectively and significantly improving their quality of life," said Dr. Abraham Havron, CEO of PROLOR.

Despite the very positive price action since we began to talk about the stock in late December, we continue to believe that Prolor is a winner and that they are poised to make great strides in the months and years shead. We anticipate that they will meet moree milestones and generate more positive news as we move ahead in 2012.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter